Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
25
BDTX Quote, Financials, Valuation and Earnings
Last price:
$2.22
Seasonality move
:
4.48%
Day range:
$2.09 - $2.26
52-week range:
$2.09 - $7.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.29x
Volume:
792.4K
Avg. volume:
485.9K
1-year change:
-16.04%
Market cap:
$125.9M
Revenue:
--
EPS (TTM):
-$1.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics
|
-- | -$0.36 | -- | -8.33% | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
IDYA
IDEAYA Biosciences
|
$3.6M | -$0.60 | -3.9% | -18.55% | $55.79 |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
VNDA
Vanda Pharmaceuticals
|
$49.2M | -- | 15.41% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics
|
$2.23 | -- | $125.9M | -- | $0.00 | 0% | -- |
|
IBIO
iBio
|
$2.48 | -- | $22.7M | -- | $0.00 | 0% | -- |
|
IDYA
IDEAYA Biosciences
|
$25.61 | $55.79 | $2.2B | -- | $0.00 | 0% | 83.40x |
|
NBY
NovaBay Pharmaceuticals
|
$0.53 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
PTN
Palatin Technologies
|
$0.97 | -- | $18.9M | -- | $0.00 | 0% | -- |
|
VNDA
Vanda Pharmaceuticals
|
$4.78 | -- | $278.4M | -- | $0.00 | 0% | 1.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics
|
-- | 1.015 | -- | -- |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
IDYA
IDEAYA Biosciences
|
-- | 0.468 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
VNDA
Vanda Pharmaceuticals
|
-- | 0.761 | -- | 4.70x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDTX
Black Diamond Therapeutics
|
-- | -$18.1M | -- | -- | -- | -$11.3M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
IDYA
IDEAYA Biosciences
|
-- | -$66.9M | -- | -- | -- | -$49.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
VNDA
Vanda Pharmaceuticals
|
$45.1M | -$11M | -3.02% | -3.02% | -23.09% | -$14.7M |
Black Diamond Therapeutics vs. Competitors
-
Which has Higher Returns BDTX or IBIO?
iBio has a net margin of -- compared to Black Diamond Therapeutics's net margin of -4444.57%. Black Diamond Therapeutics's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics-- -$0.28 -- IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About BDTX or IBIO?
Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 551.69%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Black Diamond Therapeutics has higher upside potential than iBio, analysts believe Black Diamond Therapeutics is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics0 0 0 IBIOiBio0 0 0 -
Is BDTX or IBIO More Risky?
Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock BDTX or IBIO?
Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or IBIO?
Black Diamond Therapeutics quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Black Diamond Therapeutics's net income of -$15.6M is lower than iBio's net income of -$4M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics-- -- -- -$15.6M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns BDTX or IDYA?
IDEAYA Biosciences has a net margin of -- compared to Black Diamond Therapeutics's net margin of --. Black Diamond Therapeutics's return on equity of -- beat IDEAYA Biosciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics-- -$0.28 -- IDYAIDEAYA Biosciences-- -$0.60 -- -
What do Analysts Say About BDTX or IDYA?
Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 551.69%. On the other hand IDEAYA Biosciences has an analysts' consensus of $55.79 which suggests that it could grow by 117.83%. Given that Black Diamond Therapeutics has higher upside potential than IDEAYA Biosciences, analysts believe Black Diamond Therapeutics is more attractive than IDEAYA Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics0 0 0 IDYAIDEAYA Biosciences11 1 0 -
Is BDTX or IDYA More Risky?
Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IDEAYA Biosciences has a beta of 0.792, suggesting its less volatile than the S&P 500 by 20.804%.
-
Which is a Better Dividend Stock BDTX or IDYA?
Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEAYA Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. IDEAYA Biosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or IDYA?
Black Diamond Therapeutics quarterly revenues are --, which are smaller than IDEAYA Biosciences quarterly revenues of --. Black Diamond Therapeutics's net income of -$15.6M is higher than IDEAYA Biosciences's net income of -$51.8M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while IDEAYA Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 83.40x for IDEAYA Biosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics-- -- -- -$15.6M IDYAIDEAYA Biosciences83.40x -- -- -$51.8M
-
Which has Higher Returns BDTX or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Black Diamond Therapeutics's net margin of -49.65%. Black Diamond Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics-- -$0.28 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About BDTX or NBY?
Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 551.69%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Black Diamond Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Black Diamond Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics0 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is BDTX or NBY More Risky?
Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock BDTX or NBY?
Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or NBY?
Black Diamond Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Black Diamond Therapeutics's net income of -$15.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics-- -- -- -$15.6M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns BDTX or PTN?
Palatin Technologies has a net margin of -- compared to Black Diamond Therapeutics's net margin of -2357.27%. Black Diamond Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics-- -$0.28 -- PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About BDTX or PTN?
Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 551.69%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Black Diamond Therapeutics, analysts believe Palatin Technologies is more attractive than Black Diamond Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics0 0 0 PTNPalatin Technologies0 0 0 -
Is BDTX or PTN More Risky?
Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock BDTX or PTN?
Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or PTN?
Black Diamond Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Black Diamond Therapeutics's net income of -$15.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics-- -- -- -$15.6M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns BDTX or VNDA?
Vanda Pharmaceuticals has a net margin of -- compared to Black Diamond Therapeutics's net margin of -11.17%. Black Diamond Therapeutics's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.02%.
Company Gross Margin Earnings Per Share Invested Capital BDTXBlack Diamond Therapeutics-- -$0.28 -- VNDAVanda Pharmaceuticals94.65% -$0.09 $541.2M -
What do Analysts Say About BDTX or VNDA?
Black Diamond Therapeutics has a consensus price target of --, signalling upside risk potential of 551.69%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 118.38%. Given that Black Diamond Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe Black Diamond Therapeutics is more attractive than Vanda Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings BDTXBlack Diamond Therapeutics0 0 0 VNDAVanda Pharmaceuticals0 0 0 -
Is BDTX or VNDA More Risky?
Black Diamond Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.283%.
-
Which is a Better Dividend Stock BDTX or VNDA?
Black Diamond Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Black Diamond Therapeutics pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDTX or VNDA?
Black Diamond Therapeutics quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $47.7M. Black Diamond Therapeutics's net income of -$15.6M is lower than Vanda Pharmaceuticals's net income of -$5.3M. Notably, Black Diamond Therapeutics's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Black Diamond Therapeutics is -- versus 1.45x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDTXBlack Diamond Therapeutics-- -- -- -$15.6M VNDAVanda Pharmaceuticals1.45x -- $47.7M -$5.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
